216 related articles for article (PubMed ID: 21957452)
1. Natural killer cell mediated cytotoxic responses in the Tasmanian devil.
Brown GK; Kreiss A; Lyons AB; Woods GM
PLoS One; 2011; 6(9):e24475. PubMed ID: 21957452
[TBL] [Abstract][Full Text] [Related]
2. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.
Kreiss A; Brown GK; Tovar C; Lyons AB; Woods GM
Vaccine; 2015 Jun; 33(26):3016-25. PubMed ID: 25708088
[TBL] [Abstract][Full Text] [Related]
3. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
Tovar C; Pye RJ; Kreiss A; Cheng Y; Brown GK; Darby J; Malley RC; Siddle HV; Skjødt K; Kaufman J; Silva A; Baz Morelli A; Papenfuss AT; Corcoran LM; Murphy JM; Pearse MJ; Belov K; Lyons AB; Woods GM
Sci Rep; 2017 Mar; 7():43827. PubMed ID: 28276463
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.
Brown GK; Tovar C; Cooray AA; Kreiss A; Darby J; Murphy JM; Corcoran LM; Bettiol SS; Lyons AB; Woods GM
Immunol Cell Biol; 2016 Aug; 94(7):673-9. PubMed ID: 27089941
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
[TBL] [Abstract][Full Text] [Related]
6. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.
Pye R; Patchett A; McLennan E; Thomson R; Carver S; Fox S; Pemberton D; Kreiss A; Baz Morelli A; Silva A; Pearse MJ; Corcoran LM; Belov K; Hogg CJ; Woods GM; Lyons AB
Front Immunol; 2018; 9():259. PubMed ID: 29515577
[TBL] [Abstract][Full Text] [Related]
7. Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.
Tovar C; Patchett AL; Kim V; Wilson R; Darby J; Lyons AB; Woods GM
PLoS One; 2018; 13(4):e0196469. PubMed ID: 29702669
[TBL] [Abstract][Full Text] [Related]
8. Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer.
Peel E; Belov K
Mamm Genome; 2018 Dec; 29(11-12):731-738. PubMed ID: 30225648
[TBL] [Abstract][Full Text] [Related]
9. Devil Facial Tumor Disease.
Pye RJ; Woods GM; Kreiss A
Vet Pathol; 2016 Jul; 53(4):726-36. PubMed ID: 26657222
[TBL] [Abstract][Full Text] [Related]
10. The toll-like receptor ligands Hiltonol
Patchett AL; Tovar C; Corcoran LM; Lyons AB; Woods GM
Dev Comp Immunol; 2017 Nov; 76():352-360. PubMed ID: 28689773
[TBL] [Abstract][Full Text] [Related]
11. Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.
Woods GM; Howson LJ; Brown GK; Tovar C; Kreiss A; Corcoran LM; Lyons AB
J Immunol; 2015 Jul; 195(1):23-9. PubMed ID: 26092814
[TBL] [Abstract][Full Text] [Related]
12. Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).
Ujvari B; Hamede R; Peck S; Pemberton D; Jones M; Belov K; Madsen T
Sci Rep; 2016 Apr; 6():25093. PubMed ID: 27126067
[TBL] [Abstract][Full Text] [Related]
13. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells.
Kreiss A; Wells B; Woods GM
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):135-7. PubMed ID: 19264365
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii).
Kreiss A; Fox N; Bergfeld J; Quinn SJ; Pyecroft S; Woods GM
Dev Comp Immunol; 2008; 32(5):544-53. PubMed ID: 17988737
[TBL] [Abstract][Full Text] [Related]
15. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Flies AS; Lyons AB; Woods GM
Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624
[TBL] [Abstract][Full Text] [Related]
16. Season, weight, and age, but not transmissible cancer, affect tick loads in the endangered Tasmanian devil.
Belkhir S; Hamede R; Thomas F; Ujvari B; Dujon AM
Infect Genet Evol; 2022 Mar; 98():105221. PubMed ID: 35065301
[TBL] [Abstract][Full Text] [Related]
17. Mouse Model of Devil Facial Tumour Disease Establishes That an Effective Immune Response Can be Generated Against the Cancer Cells.
Pinfold TL; Brown GK; Bettiol SS; Woods GM
Front Immunol; 2014; 5():251. PubMed ID: 24904594
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease.
Phalen DN; Frimberger AE; Peck S; Pyecroft S; Harmsen C; Lola S; Moore AS
Vet J; 2015 Dec; 206(3):312-6. PubMed ID: 26538144
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil.
Patchett AL; Latham R; Brettingham-Moore KH; Tovar C; Lyons AB; Woods GM
Dev Comp Immunol; 2015 Nov; 53(1):123-33. PubMed ID: 26182986
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal plasticity of devil facial tumour cells during in vivo vaccine and immunotherapy trials.
Patchett AL; Tovar C; Blackburn NB; Woods GM; Lyons AB
Immunol Cell Biol; 2021 Aug; 99(7):711-723. PubMed ID: 33667023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
